🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🌍✨ Today is #WorldCancerDay! This year’s theme: #UnitedByUnique. ESTRO president Matthias Guckenberger reflects on how unity, innovation & patient empowerment shape the future of cancer care. 👉 Read his message: bit.ly/40Lgq3A #CancerCare #Radiotherapy #RadiationOncology #radonc

🆕A systematic review & meta-analysis comparing SBRT, RFA, MWA, & cryoablation for localized renal cell carcinoma (RCC). 🔹 Local Control Rates: ✅ SBRT: 99% (1y), 97% (2y), 95% (5y) ✅ RFA: 96% (1y), 95% (2y), 92% (5y) ✅ MWA: 97% (1y), 95% (2y), 86% (5y) ✅ Cryoablation: 95%

SBRT in Oligometastatic CRPC: ☢️Adding SBRT to ADT+Enza doubled rPFS and delayed time to next therapy. OS data immature but signals lower risk of death. Minimal toxicity. ☢️Should SBRT become standard in oligometastatic CRPC? ASCO OncoAlert #GU25 #cancer #oncology

🔍 Are you an oncologist? Ever felt like you don’t deserve your success? Striving for perfection but battling impostor syndrome? 🚀 Join our global study! 📌 Take the survey: docs.google.com/forms/d/1KQzM3… 🕒 <10 min | 🔒 100% anonymous 📩 Share with your colleagues!

🔔📣📢 RADIOSA full paper is finally out! Read our publication now online on The Lancet Oncology! Randomised trial in the metachronous oligomets hormone-sensitive PCa setting reporting improved clinical PFS with the combination of SBRT and a short course of ADT!

🔥 Much awaited- SANO trial published (Phase 3, non-inferiority trial, 🇳🇱) 309 patients with esophageal cancer with complete response after neoadjuvant chemoradiation (EUS, biopsy, PET) ➡️198 active surveillance, 111 standard surgery. ‼️74% adenocarcinoma 🕰️ Median follow-up

Had an incredible three weeks in Milan at the European Institute of Oncology Proton Center! Learned so much and am deeply grateful for the mentorship of Prof. Barbara Jereczek. It was an honor to meet and work with her. Thank you for this invaluable experience! prof. Barbara Jereczek-Fossa

❓ Role of SBRT-only in hormone-sensitive oligometastatic prostate cancer ❓ Value of 6-months ADT added to SBRT ❓ Appropriate endpoints Virtual Grand Rounds in Radiation Oncology usz.ch/en/events/virt… Proudly presenting: prof. Barbara Jereczek-Fossa Wed April 2nd 17:00 – 17:30 CET 👇

Predicting acute and late toxicity in prostate cancer stereotactic ablative radiotherapy: the role of dosimetric pa… pubmed.ncbi.nlm.nih.gov/39792260/

🚨 New Editorial Alert! We challenge the current guidelines: Why excluding the prepontine cistern from WVI in germ cell tumors might be a risky shortcut. Check out our thoughts in the latest issue of IJROBP. #RadOnc IJROBP - The Red Journal Alper Kahvecioglu MD authors.elsevier.com/c/1kwuV_8CJj2N…

In this new Editorial IJROBP - The Red Journal, we discuss the COG Atlas for germ cell tumors and support the recommendation by Alper Kahvecioglu MD and Melek Tugce Yilmaz MD to include the prepontine cistern in the whole ventricular volume. Shannon M MacDonald redjournal.org/article/S0360-… ASTRO

Every Other Day or Once a Week: Long-term Oncological Outcomes in the Phase 2 PATRIOT Trial of Prostate Stereotacti… pubmed.ncbi.nlm.nih.gov/40288917/

Big news from #ESTRO25! Nivolumab + CRT shows striking improvement in MIBC outcomes for patients not undergoing RC! BCFFS: 70.3% vs 43.4% OS at 2y: 86.8% vs 60.5% (p=0.005) Well tolerated + good onc outcomes = a game-changer? Time for Phase III trial! #TMT #MIBC #immunotherapy

GROG Gazete'nin Mayıs '25 sayısı yayında!🥁 Bu projenin editörü olmak hem çok gurur verici hem de keyifliydi. Şimdi sözü yeni ekibe devretme zamanı. Yeni sayıları heyecanla bekliyorum! 🙌 Alper Kahvecioglu MD Turkish Society For Radiation Oncology

Reirradiation (reRT) is reshaping cancer care—offering hope for recurrent tumors w/ advanced precision techniques like IMRT & SBRT. Multidisciplinary care, imaging, and innovation are key. New #OpenAccess review by Andratschke et al: acsjournals.onlinelibrary.wiley.com/doi/full/10.33… OncoAlert #RadOnc

🔥Happening now! Case-based overview of the care of pts with esophagus cancer! Overview of recent peri-op landscape, shaping path from: Surgery alone➡️peri-op MAGIC➡️CROSS➡️peri-op FLOT, and upcoming➡️FLOT + Durva (MATTERHORN) #ASCO25

🔥NSABP- B51 is out! Practice changing trial supporting RT de-escalation in cN1, ypN0 breast cancer 👉longer follow up desired 👉applicability across subtypes? 👉Impact of more modern systemic therapies ? NRG Oncology ASTRO #BreastCancer nejm.org/doi/full/10.10…

👉🏻 Our new publication suggests no survival benefit from adding CHT to RT in stage II NPC 👉🏻 While RT alone was effective overall, selected patients might still benefit from tailored use of CHT⁉️ 👉🏻 CONC: More data needed ✅ Melek Tugce Yilmaz MD Sepideh Mohammadipour onkder.org/abstract.php?l…

🚀 New from our clinic! "Gyroscopic Radiosurgery-Based Lattice Therapy for intracranial tumors" now published! 📝 Read our innovative article & support us by voting in the “Dedicated Cranial Radiosurgery” competition! 🔗cureus.com/articles/36963… Cureus Sepideh Mohammadipour